

1 **Whole genome analysis in *APOE4* homozygotes identifies the *DAB1-RELN***
2 **pathway in Alzheimer's disease pathogenesis**

3

4 Matthew Bracher-Smith, PhD¹, Ganna Leonenko, PhD², Emily Baker, PhD², Karen Crawford, MSc¹,

5 Andrew C. Graham, MSc³, Dervis A. Salih, PhD³, Brian W. Howell, PhD⁴, John Hardy, PhD^{3*}, Valentina

6 Escott-Price, PhD^{1,2*}

7

8 *Affiliations*

9 1 MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine &

10 Clinical Neurosciences, Cardiff University, UK

11 2 Dementia Research Institute, Cardiff University, UK

12 3 Dementia Research Institute, University College London, UK

13 4 Neuroscience and Physiology, State University of New York, USA

14

15 *Corresponding Authors*

16 Valentina Escott-Price

17 Tel. +44 2920 688429

18 Address: Hadyn Ellis Building, Cardiff University, Maindy Road, Cardiff, CF24 4HQ, UK

19 e-mail: escottpricev@cardiff.ac.uk

20

21 John Hardy

22 Tel. +44 2031 086802

23 Address: UCL Cruciform Building, Gower Street, London, WC1E 6BT, UK

24 e-mail: j.hardy@ucl.ac.uk

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract**

27 The *APOE*- ϵ 4 allele is known to predispose to amyloid deposition and consequently is
28 strongly associated with Alzheimer's disease (AD) risk. There is debate as to whether the
29 *APOE* gene accounts for all genetic variation of the *APOE* locus. Another question which
30 remains is whether *APOE*- ϵ 4 carriers have other genetic factors influencing the progression
31 of amyloid positive individuals to AD. We conducted a genome-wide association study in a
32 sample of 5,390 *APOE*- ϵ 4 homozygous (ϵ 4 ϵ 4) individuals (288 cases and 5,102 controls)
33 aged 65 or over in the UK Biobank. We found no significant associations of SNPs in the *APOE*
34 locus with AD in the sample of ϵ 4 ϵ 4 individuals. However, we identified a novel genome-
35 wide significant locus associated to AD, mapping to *DAB1* (rs112437613, OR=2.28, CI=1.73-
36 3.01, $p=5.4 \times 10^{-9}$). This identification of *DAB1* led us to investigate other components of the
37 *DAB1-RELN* pathway for association. Analysis of the *DAB1-RELN* pathway indicated that the
38 pathway itself was associated with AD, therefore suggesting an epistatic interaction
39 between the *APOE* locus and the *DAB1-RELN* pathway.

40

41 Introduction

42 Genome wide association studies (GWAS) have led to the identification of many genetic loci
43 influencing the risk of dementia [1]. However, none of these approach the importance of
44 the *APOE* locus [2] where the *APOE-ε4* allele has a frequency of ~15% in controls and has a
45 risk ratio of >3 in cases. Other loci with allele frequencies of >1% have risk ratios of <1.4.
46 Recent studies have shown that the *APOE* genotype is almost solely responsible for amyloid
47 deposition whereas other components of Alzheimer's disease (AD) genetic risk contribute to
48 the occurrence of dementia in the context of amyloid deposition [3]. Furthermore,
49 neuropathologic studies have shown that clinical diagnoses in Alzheimer series had a
50 diagnostic accuracy of around 80%: this accuracy is implied by analyses comparing the large
51 clinical GWAS with the smaller neuropathologic GWAS, leading to the concern that these
52 larger GWAS are contaminated by other diagnoses. This concern is heightened by the
53 reports of loci for frontotemporal dementia in case series labelled as Alzheimer's disease in
54 the most recent GWAS for the disorder [4].

55

56 With this background, we have undertaken an AD GWAS in individuals who are *APOE-ε4*
57 homozygotes for three reasons. First, because in this group diagnostic accuracy is very high;
58 second, to assess whether in this context there is additional genetic risk at the *APOE* locus;
59 and third, to assess which previously reported loci are replicated in these cases and whether
60 there are any novel loci we can identify which are dependent on *APOE-ε4* homozygosity.
61 This study was possible in the UK Biobank [5] because it has a very large cohort, with a
62 sufficient number (for statistical analyses) of *APOE-ε4* homozygotes, where many
63 participants are now reaching the age where they are at risk.

64 Here we report that the *APOE* allele alone accounts for the AD risk in the LD block on
65 chromosome 19 in the European population. Furthermore, in *APOE*- ϵ 4 homozygotes, we
66 identify AD risk associated with the *DAB1* gene that encodes a synapse regulatory protein.
67 Subsequent analyses revealed a gene set association with the *DAB-RELN* pathway.

68

69 **Methods**

70 *Phenotypes*

71 Individuals from the UK Biobank were considered if they self-reported as white British and
72 were of similar genetic ancestry by principal component analysis (UK Biobank field 22006),
73 were unrelated (kinship coefficient < 0.04) and if they had not withdrawn consent to
74 participate under UK Biobank. Participants were further excluded if they showed excessive
75 missingness or sex chromosome aneuploidy, were outliers for heterozygosity, had
76 mismatching self-reported and inferred sex from genotyping data, and had over 10 putative
77 third-degree relatives. AD definition was derived using ICD-10 codes in hospital and death
78 records. Individuals were coded as cases where dementia in Alzheimer's disease (ICD-10
79 code F00) or Alzheimer's disease (code G30) were present. Controls were defined as those
80 without F00, G30, vascular dementia (F01), dementia in other diseases (F02) and
81 unspecified dementia (F03). *APOE* status was assigned to each individual, as defined by SNPs
82 rs7412 and rs429358 which are both present on the Affymetrix Axiom genotyping array
83 used. After quality control and restriction to *APOE*- ϵ 4 homozygous individuals aged 65 or
84 over, 288 cases and 5,102 controls were included in analysis.

85

86 *Genetic quality control*

87 The UK Biobank genetic data from the haplotype reference consortium (HRC), imputed by
88 the UK Biobank [6], was restricted to biallelic SNPs (minor allele frequency > 0.05) with
89 Hardy-Weinberg equilibrium > 10^{-6} , INFO>0.4 and posterior probability>0.4. After quality
90 control, 5,349,830 SNPs were included in analysis.

91

92 *Analysis*

93 Association analysis was conducted in PLINK2 [7] on UK Biobank dosage data using most
94 recently recorded age, sex and the first 15 principal components (field 22009) as covariates.

95 The significant findings (with the logistic regression) were further tested with Cox
96 proportional-hazards regression (while controlling for the covariates) where the censoring
97 occurred when a participant reported AD, allowing for the fact that some individuals have
98 not reached the age at onset and may develop the disease given time.

99

100 The enrichment analysis of significant SNPs (at 5% significance level) or for SNPs showing
101 the same direction of the effect (assuming that the chance to have the same direction of
102 effect is 50%) was performed with `binom.test()` function in R.

103

104 The power calculations were performed with `qnorm()` function in R-statistical package at
105 nominal 5% significance level (unless specified otherwise), where Z-score was estimated as
106 $\log(\text{OR})/\text{var}$ with the $\log(\text{OR})$ as reported in the GWAS. In the Wightman et al. study [4], the
107 largest OR was selected from the reported ORs in the list of contributing studies. The
108 variance estimated as the inverse variance, with allele frequencies in cases and controls

109 (corresponding to the SNP OR), and the sample size as in our study (N cases = 288, N
110 controls = 5,102). Plots of regional associations were created using LocusZoom [8].

111
112 Epistasis was defined as deviation from joint two SNPs linear effects in the logistic
113 regression model (known as statistical interaction). Significance of the interaction term was
114 assessed using --epistasis option PLINK [7], accounting for the same covariates as above. The
115 interaction plots were produced using matplotlib in python [9].

116
117 Gene-based analysis was run by MAGMA using FUMA v1.3.7 [10, 11]. Competitive setting of
118 MAGMA was also used to test the candidate pathways for the enrichment of AD significant
119 genes as compared to the rest of the genome.

120

121 *DAB1-RELN pathway analysis*

122 The canonical Reelin-Dab1 signalling pathway has been studied extensively in mouse
123 neurons and brain [12]. For analysis, we divided the pathway into three sections: a) the
124 receptor complex, (Reelin, the receptors ApoER2, VLDLR, the adaptor protein DAB1, and the
125 tyrosine kinases SRC, FYN and YES) [13–16], b) branch 1 that regulates N-cadherin (CRK,
126 CRKL, C3G, RAP1, P120 catenin, N-cadherin) [17–19] and c) branch 2 that is involved in
127 microtubule-associated protein tau (MAPT) phosphorylation (PI3K, PDK, AKT, GSK3, STK25)
128 [20–22]. We converted these mouse proteins to the homologous human genes with the
129 BioConductor function in R and the NCBI database (www.ncbi.nlm.nih.gov/) yielding: a)

130 *RELN, LRP8, VLDLR, DAB1, SRC, FYN, YES1, b) CRK, CRKL, RAPGEF1, RAP1A, CTNND, CDH2, c)*
131 *PIK3CA, PDK1, PDK2, GSK3B, AKT1, STK25.*

132

133

134 **Results**

135 We present the results in the following order: (a) analysis of the *APOE* locus, (b) analysis of
136 other previously reported GWAS in these cases, (c) identification of the *DAB1* locus as a
137 genome wide for disease, (d) assessment of other loci in the same *DAB1-RELN* pathway.

138

139 *APOE* locus

140 No suggestive variants were identified in the *APOE* gene or surrounding region
141 (chromosome 19: 44.5-46.5 Mb, as defined previously [23]) with the lowest *p*-value at 0.003
142 within 1Mb of the *APOE* gene (Supplementary Figure S1) in *APOE*- ϵ 4 homozygotes.

143

144 *Other GWAS Hits*

145 Loci previously reported as GWAS for association with Alzheimer's disease status did not
146 show a strong replication in the current analysis of *APOE*- ϵ 4 homozygotes only
147 (Supplemental Table S1). Though the power to detect the GWAS-reported effect sizes in this
148 sample is not sufficient (see last column of Supplemental Table S1), four loci in *CD33*
149 (*p*=0.004), *IQCK* (*p*=0.009), *LILRB2* (*p*=0.005) and *SORL1* (*p*=0.007, MAF=0.04) had the
150 strongest evidence for association in the current analysis and a consistent direction of effect
151 between the current and previous GWAS. Weaker but nominally significant associations
152 with the consistent direction of the effect were also observed in the *APH1B* (*p* = 0.024), *BIN1*

153 ($p=0.011$), *SEC61G* ($p=0.015$) and *SNX1* ($p=0.048$) genes. In total, eight out of 77 SNPs
154 (previously reported as genome-wide significant and available in our study), replicated at
155 0.05 significance level with the same direction of association, which is statistically greater
156 than chance ($p=0.038$). In addition, 53/77 (69%) SNPs have same direction of effect in the
157 current analysis and previous GWAS which is greater than expected by chance ($p = 0.001$).

158

159 *Identification of DAB1 as a locus*

160 Multiple novel genome-wide significant intronic SNPs were present in *DAB1* (lead SNP:
161 rs112437613, OR=2.28, CI=1.73-3.01, $p=5.36 \times 10^{-9}$; Figure 1 and Supplemental Figure S2,
162 Table 1). The minor allele T was associated with disease risk (MAF=6% in non-AD and 12% in
163 AD $\epsilon 4\epsilon 4$ -participants of the UK Biobank). To allow for the fact that some individuals might
164 not have reached the age at onset, we fit a survival regression model (adjusting for PCs and
165 sex). The result remained highly significant (Hazard Ratio=2.27, CI=1.75-2.95, $p= 7.8 \times 10^{-10}$).
166 The Kaplan-Meier graph (Figure 2) demonstrates that probability of getting the disease (y-
167 axis) earlier (x-axis) is higher as the number of the risk alleles of rs112437613 SNP increases.

168

169 The frequency of this allele is reported 4%-7% in European population cohorts
170 (1000Genomes, TOPMED, GnomAD, Estonian, ALSPAC-UK, TWINSUK, Northern Sweden, see
171 <https://genome.ucsc.edu>). However, this SNP (and others in LD with it) did not show even a
172 nominal association to AD in recent GWAS that did not preselect for the $\epsilon 4\epsilon 4$ genotype: e.g.
173 a study of 21,982 cases and 41,944 controls the p-values were $p \sim 0.5$ (see Table 1) [24].
174 Indeed, in a case/control sample (without screening for the *APOE*- $\epsilon 4$ status), the effect size
175 of this SNP would be OR=1.016, as the proportion of cases, with both T allele of
176 rs112437613 and $\epsilon 4\epsilon 4$, is 0.016 ($=\text{MAF}(\epsilon 4)^2 * \text{MAF}(\text{rs112437613 in } \epsilon 4\epsilon 4) = 0.36^2 * 0.12$, where

177 0.36 is the $\epsilon 4$ allele frequency in cases [25], and, similarly, of controls is 0.001. Therefore,
178 the frequencies of the T allele in the overall sample are expected to be 0.061 in cases and
179 0.06 in controls, and consequently, the power to detect it with the sample size of the [24]
180 study is close to 0 ($\sim 3 \times 10^{-7}$).

181
182 This observation led us to test for an epistatic effect in the whole sample of the UK Biobank
183 aged 65+ (N=229,748). There was indeed significant epistasis between the two loci
184 ($p=1.5 \times 10^{-5}$), whereas the effect of the T allele (rs112437613) was positive (OR=1.16,
185 SE=0.11), but only nominally significant ($p=0.021$), providing evidence for cooperation
186 between these two loci. The risk allele frequencies in this locus depending on *APOE* and AD
187 status are shown in Table S2 and the risk of AD, depending on the genotypes at the two loci,
188 is shown in Figure 5. The figure and table clearly show a statistical epistatic effect, where
189 the disease risk is only visible in people with $\epsilon 4\epsilon 4$ genotypes.

190

191 *Candidate analysis of other loci in the Reelin-DAB1 pathway*

192 *Dab1* encodes a cytoplasmic signalling adaptor that is predominantly expressed in neurons
193 where it acts downstream of the extracellular ligand Reelin to regulate brain lamination
194 during development [26–29]. Since Reelin-DAB1 signalling also performs an important role
195 in the adult brain by promoting excitatory synapse maturation [30, 31] and modulating
196 synaptic plasticity, learning and memory [32–35], we explicitly looked at the SNPs
197 associations in the *RELN* gene (chr7:103,112,231-103,629,963). This gene is comprised of
198 2002 SNPs and the most significant SNP was rs171331137 (chr7:103479651) with OR=1.51
199 (SE=0.11), $p=2.4 \times 10^{-4}$ (Supplemental Figure S3). Similar to *DAB1*, we tested this SNP for

200 interaction with *APOE-ε4* in the whole UK Biobank sample. The interaction term was not
201 significant ($p=0.24$), however the pattern of AD risk based on the pair of these markers was
202 similar to *DAB1* (Supplemental Figure S4).

203

204 The Reelin ligand and DAB1 adaptor proteins are bridged by two partially redundant
205 transmembrane receptors APOER2 (LRP8) and VLDLR [15, 16]. Reelin binding to its receptors
206 recruits DAB1 to their cytoplasmic tails activating the SRC family kinases, SRC, FYN and YES
207 [13, 14, 36]. This leads to the increased tyrosine phosphorylation of DAB1 and the
208 recruitment of additional signalling adaptor proteins that activate two key branches of the
209 pathway (Figure 6). One branch is initiated by the binding of CRK and CRKL to phospho-
210 DAB1, leading to the phosphorylation of C3G (*RAPGEF1*) and activation of RAP1 (*RAP1A*) [17,
211 18]. This leads to the upregulation of N-Cadherin (*CDH2*) cell-surface expression through
212 engagement with p120 catenin (*CTNND*) [19]. A second branch is regulated by the binding
213 of phosphatidylinositol 3-kinase (*PIK3KA*) to DAB1 leading to the activation of PDK (*PDK1*,
214 *PKD2*) and AKT (*AKT1*) ultimately suppressing the activity of the MAPT kinase GSK3 [20]. In
215 mouse, deficiency of DAB1 has been shown to augment tau-phosphorylation and Stk25 has
216 been implicated in this process [21, 22]. Since the signalling complex and the downstream
217 pathways have potential significance in the development of AD, we tested their associated
218 genes for enrichment in AD.

219

220 Using the results of the gene-based analyses described above, we tested whether the
221 receptor complex and the two pathway branches contained significantly more AD
222 associated genes as compared with the rest of the genome. We found that they were

223 significantly (or almost significantly) enriched for genes associated to AD in the *APOE-ε4*
224 homozygotes (p-values 0.06, 0.009, 0.075, for the receptor complex and branches 1 and 2,
225 respectively). The strongest significance was achieved when we combined the receptor
226 complex and the two branches of the pathway (p=0.0055). Table 2 shows the details for
227 each gene.

228

229 **Discussion**

230 *No residual association at the APOE locus*

231 *APOE-ε4* is the strongest genetic risk factor for late onset AD. *APOE-ε4* carriers have
232 elevated risk for AD and earlier age-at-onset, with *APOE-ε4* homozygotes at the highest risk
233 [37, 38]. Many loci beyond *APOE* have been reported as associated with disease in
234 increasingly large GWAS and meta-analyses, with over 80 susceptibility loci reported
235 collectively [4, 39, 40]. We find no evidence to support the role of additional loci in an
236 extended 2Mb region around *APOE* in *APOE-ε4* homozygotes. This is supported by previous
237 work on risk in the *APOE* region after adjusting for number of $\epsilon 4$ alleles [41, 42]. It is
238 therefore unlikely that variants contribute additional risk to AD in the *APOE* region in *APOE-*
239 $\epsilon 4$ homozygotes although association has previously been reported in *PVRL2* and *APOC1* in
240 Chinese samples after adjusting for number of *APOE-ε4* alleles [43]. Variants around *APOE*
241 may explain additional variation in risk in populations where polymorphisms are in less
242 pronounced LD with rs429358, and residual variability in *APOE-ε3* carriers may still modify
243 risk for the disease [44].

244

245 *Other established GWAS hits*

246 This study does not have statistical power to reliably determine whether all the previously
247 reported GWAS hits are associated with disease in *APOE-ε4* homozygotes or whether those
248 which do show direct evidence for association (nominal significance) are grouped in any
249 particular pathway.

250

251 *Association with DAB1*

252 Putative novel risk SNPs with strong evidence for association were mapped to the *DAB1*
253 gene on chromosome 1. Roles for *DAB1* and *RELN* have previously been suggested in AD
254 primarily based on studies in mice [36, 45–48] and functional genomic analysis in humans
255 [49], but genome-wide association in humans has been lacking. However, it has been shown
256 that the expression of *DAB1* and *RELN* are altered in AD brains [50–52]. *DAB1* interacts with
257 Asp-Pro-any residue-Tyr (NPXY) motifs in the cytoplasmic domains of amyloid precursor
258 protein (APP) as it does with similar motifs in the cytoplasmic tails of the Reelin receptors
259 through its N-terminal PTB domain [53, 54]. The NPXY motif is required for APP
260 internalization and its deletion reduces A β production [55]. *DAB1* association with APP has
261 been shown to reduce amyloidogenic processing [36], which suggests it is involved in the
262 intracellular trafficking of APP. Reelin also reduces A β production in HEK293 cells that don't
263 express *DAB1* [47]. In a mouse model of AD, heterozygosity of *Reln* increases the
264 accumulation of A β plaques [45], suggesting that the pathway physiologically alters APP
265 cleavage in a manner that would protect against AD. In addition, homozygous loss-of-
266 function in *Reln* and *Dab1* have been shown to augment tau-phosphorylation [21]. Reelin
267 overexpression reduces abnormal somatodendritic localization of phosphor-Tau, A β plaques
268 and synaptic loss in AD model mice [46, 48]. Thus there are links between the Reelin-*DAB1*

269 pathway and the two major pathological features of AD. In this study, both examined
270 branches of the *DAB1-RELN* pathway had genes with significant association with AD. SNPs
271 near *RAP1A* were significant; however, it remains to be determined if this branch regulates
272 A β phosphor-Tau or another AD related pathology. The other major pathway downstream
273 of Reelin-DAB1 has been associated with tau-phosphorylation and both *AKT* and *PIK3KA*
274 from this branch were significantly associated with AD.

275

276 The dependence of the association between *DAB1/RELN* and AD on *APOE- ϵ 4* homozygosity
277 is intriguing since there are several links between the Reelin pathway and APOE. The Reelin
278 receptors are also APOE receptors and DAB1 binds the NPXY motifs in the cytoplasmic tails
279 of other LDL-superfamily receptors [53, 54, 56], such as LDL-receptor related protein 1 that
280 has roles in APOE/A β internalization and clearance [57]. Recent studies show that *APOE- ϵ 4*
281 reduces recycling of ApoER2 back to the plasma membrane making the cells less responsive
282 to Reelin [58] and that Reelin protects against the toxic effects of A β on synapses [59]. Thus
283 in *APOE- ϵ 4* homozygotes, one can imagine a threshold effect with high *APOE- ϵ 4* driving a
284 pathological cycle by reducing the effects of DAB1 and RELN signalling including its normal
285 function to reduce A β production/toxicity and/or MAPT-phosphorylation.

286

287 While the effect the SNPs have on the function of *DAB1* or other pathway genes remain to
288 be determined, based on previous studies it would seem likely that they cause a partial loss-
289 of-function that is potentially age dependent or cell-type specific in nature and would result
290 in altered expression (eQTL) or splicing (sQTL). More than partial disruption of activity would
291 likely lead to a developmental disorder in the homozygous individuals similar to loss-of-

292 function alleles for *Dab1* in mice and *RELN* in humans and mice [60]. The significant SNPs
293 identified here fall in intron 2 and are found in 4-7% of the population. Interestingly *DAB1*
294 exomic variation is constrained and few variants are more prevalent than 1-2% (GnomAD)
295 suggesting that the identified SNPs do not flag an alteration in the *DAB1* coding sequence.
296 *DAB1* is alternatively spliced and differentially expressed most notably in a cell-type specific
297 manner [26, 61–63]. Alternative splicing has been shown to regulate exons encoding a
298 subset of the phosphorylation sites and a C-terminal exon altering *Dab1* functionality in
299 mice. We note that humans have a read through variant of exon 3 that would lead to
300 transcriptional termination 14 residues later (variant 9) that has not been identified in mice.
301 It encodes the first part of the phosphotyrosine binding (PTB) domain residues 37-69, but it
302 is likely to be functionally inert since the PTB domain extends to residue 171 [64]. With this
303 complexity and the size of the *DAB1* gene, over 1 Mb, it could take significant effort to
304 dissect the consequence of the SNPs identified here on gene function and AD.

305

306 In conclusion, we find a novel genome-wide significant hit in *DAB1* in an *APOE-ε4*
307 homozygote AD GWAS. This seems to be a hit only in *APOE-ε4* homozygotes. Furthermore,
308 it seems that this association marks a more general importance of the *DAB1-RELN* pathway
309 in disease pathogenesis. It is not clear why this pathway should be of such importance in
310 *APOE-ε4* homozygotes only, but a clue may be that such individuals have particularly dense
311 Aβ pathology and one can imagine that this pathway either has a role in modulating APP
312 processing or in driving tau-phosphorylation in a manner that is dependent on high Aβ
313 levels. This work suggests that *DAB1* has a protective role in late onset AD and highlights the
314 importance of resolving the mechanism that likely involves the REELIN-*DAB1* pathway for
315 therapeutic development.

316

317 **Funding**

318 This work was largely funded by the UK DRI, which receives its funding from the DRI Ltd,
319 funded by the UK Medical Research Council (UKDRI-3003), Alzheimer’s Society and ARUK. JH
320 is supported by the Dolby Foundation, and by the National Institute for Health Research
321 University College London Hospitals Biomedical Research Centre. D.A.S. also received
322 funding from the Alzheimer’s Research UK (ARUK) pump priming scheme via the UCL
323 network. VEP is supported by Joint Programming for Neurodegeneration (JPND) - (MRC:
324 MR/T04604X/1).

325

326 **Competing interests**

327 The authors report no competing interests.

328 **References**

- 329 1. Hardy J, Escott-Price V. Genes, pathways and risk prediction in Alzheimer’s disease.
330 Hum Mol Genet 2019; 28: R235–R240.
- 331 2. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson J V., Lince DH, et al. A High-
332 Density Whole-Genome Association Study Reveals That *APOE* Is the Major
333 Susceptibility Gene for Sporadic Late-Onset Alzheimer’s Disease. J Clin Psychiatry
334 2007; 68: 0–0.
- 335 3. Leonenko G, Shoai M, Bellou E, Sims R, Williams J, Hardy J, et al. Genetic risk for
336 alzheimer disease is distinct from genetic risk for amyloid deposition. Ann Neurol
337 2019; 86: 427–435.
- 338 4. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. A
339 genome-wide association study with 1,126,563 individuals identifies new risk loci for
340 Alzheimer’s disease. Nat Genet 2021 539 2021; 53: 1276–1282.
- 341 5. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open
342 Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of
343 Middle and Old Age. PLOS Med 2015; 12: e1001779.
- 344 6. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
345 resource with deep phenotyping and genomic data. Nature 2018; 562: 203–209.
- 346 7. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
347 PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015; 4: 7.
- 348 8. Boughton AP, Welch RP, Flickinger M, VandeHaar P, Taliun D, Abecasis GR, et al.
349 LocusZoom.js: interactive and embeddable visualization of genetic association study
350 results. Bioinformatics 2021; 37: 3017–3018.
- 351 9. Hunter JD. Matplotlib. Comput Sci Eng 2007; 9: 90–95.

- 352 10. Leeuw CA de, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set
353 Analysis of GWAS Data. *PLoS Comput Biol* 2015; 11.
- 354 11. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and
355 annotation of genetic associations with FUMA. *Nat Commun* 2017 81 2017; 8: 1–11.
- 356 12. Lee GH, D’Arcangelo G. New insights into reelin-mediated signaling pathways. *Front*
357 *Cell Neurosci* 2016; 10: 122.
- 358 13. Arnaud L, Ballif BA, Förster E, Cooper JA. Fyn Tyrosine Kinase Is a Critical Regulator of
359 Disabled-1 during Brain Development. *Curr Biol* 2003; 13: 9–17.
- 360 14. Bock HH, Herz J. Reelin Activates Src Family Tyrosine Kinases in Neurons. *Curr Biol*
361 2003; 13: 18–26.
- 362 15. D’Arcangelo G, Homayouni R, Keshvara L, Rice DS, Sheldon M, Curran T. Reelin Is a
363 Ligand for Lipoprotein Receptors. *Neuron* 1999; 24: 471–479.
- 364 16. Hiesberger T, Trommsdorff M, Howell BW, Goffinet A, Mumby MC, Cooper JA, et al.
365 Direct Binding of Reelin to VLDL Receptor and ApoE Receptor 2 Induces Tyrosine
366 Phosphorylation of Disabled-1 and Modulates Tau Phosphorylation. *Neuron* 1999; 24:
367 481–489.
- 368 17. Ballif BA, Arnaud L, Arthur WT, Guris D, Imamoto A, Cooper JA. Activation of a
369 Dab1/CrkL/C3G/Rap1 Pathway in Reelin-Stimulated Neurons. *Curr Biol* 2004; 14: 606–
370 610.
- 371 18. Franco SJ, Martinez-Garay I, Gil-Sanz C, Harkins-Perry SR, Müller U. Reelin Regulates
372 Cadherin Function via Dab1/Rap1 to Control Neuronal Migration and Lamination in
373 the Neocortex. *Neuron* 2011; 69: 482–497.
- 374 19. Jossin Y, Cooper JA. Reelin, Rap1 and N-cadherin orient the migration of multipolar
375 neurons in the developing neocortex. *Nat Neurosci* 2011 146 2011; 14: 697–703.

- 376 20. Bock HH, Jossin Y, Liu P, Förster E, May P, Goffinet AM, et al. Phosphatidylinositol 3-
377 Kinase Interacts with the Adaptor Protein Dab1 in Response to Reelin Signaling and Is
378 Required for Normal Cortical Lamination *. J Biol Chem 2003; 278: 38772–38779.
- 379 21. Bricht J, Shie FS, Howell BW, Li R, Tus K, Wakeland EK, et al. Genetic Modulation of Tau
380 Phosphorylation in the Mouse. J Neurosci 2003; 23: 187–192.
- 381 22. Matsuki T, Zaka M, Guerreiro R, van der Brug MP, Cooper JA, Cookson MR, et al.
382 Identification of Stk25 as a Genetic Modifier of Tau Phosphorylation in Dab1-Mutant
383 Mice. PLoS One 2012; 7: e31152.
- 384 23. Escott-Price V, Shoai M, Pither R, Williams J, Hardy J. Polygenic score prediction
385 captures nearly all common genetic risk for Alzheimer’s disease. Neurobiol Aging
386 2017; 49: 214.e7-214.e11.
- 387 24. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-
388 analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates A β ,
389 tau, immunity and lipid processing. Nat Genet 2019 513 2019; 51: 414–430.
- 390 25. Frieden C, Garai K. Structural differences between apoE3 and apoE4 may be useful in
391 developing therapeutic agents for Alzheimer’s disease. Proc Natl Acad Sci U S A 2012;
392 109: 8913–8918.
- 393 26. Abadesco AD, Cilluffo M, Yvone GM, Carpenter EM, Howell BW, Phelps PE. Novel
394 Disabled-1-expressing neurons identified in adult brain and spinal cord. Eur J Neurosci
395 2014; 39: 579–592.
- 396 27. Howell BW, Herrick TM, Cooper JA. Reelin-induced tyrosine phosphorylation of
397 Disabled 1 during neuronal positioning. Genes Dev 1999; 13: 643.
- 398 28. Howell BW, Herrick TM, Hildebrand JD, Zhang Y, Cooper JA. Dab1 tyrosine
399 phosphorylation sites relay positional signals during mouse brain development. Curr

- 400 Biol 2000; 10: 877–885.
- 401 29. Rice DS, Sheldon M, D’Arcangelo G, Nakajima K, Goldowitz D, Curran T. Disabled-1
402 acts downstream of Reelin in a signaling pathway that controls laminar organization
403 in the mammalian brain. *Development* 1998; 125: 3719–3729.
- 404 30. Qiu S, Weeber EJ. Reelin signaling facilitates maturation of CA1 glutamatergic
405 synapses. *J Neurophysiol* 2007; 97: 2312–2321.
- 406 31. Ventruti A, Kazdoba TM, Niu S, D’Arcangelo G. Reelin deficiency causes specific
407 defects in the molecular composition of the synapses in the adult brain. *Neuroscience*
408 2011; 189: 32–42.
- 409 32. Pujadas L, Gruart A, Bosch C, Delgado L, Teixeira CM, Rossi D, et al. Reelin Regulates
410 Postnatal Neurogenesis and Enhances Spine Hypertrophy and Long-Term
411 Potentiation. *J Neurosci* 2010; 30: 4636–4649.
- 412 33. Rogers JT, Rusiana I, Trotter J, Zhao L, Donaldson E, Pak DTS, et al. Reelin
413 supplementation enhances cognitive ability, synaptic plasticity, and dendritic spine
414 density. *Learn Mem* 2011; 18: 558–564.
- 415 34. Trotter J, Lee GH, Kazdoba TM, Crowell B, Domogauer J, Mahoney HM, et al. Dab1 Is
416 Required for Synaptic Plasticity and Associative Learning. *J Neurosci* 2013; 33: 15652–
417 15668.
- 418 35. Weeber EJ, Beffert U, Jones C, Christian JM, Förster E, David Sweatt J, et al. Reelin and
419 ApoE Receptors Cooperate to Enhance Hippocampal Synaptic Plasticity and Learning
420 *. *J Biol Chem* 2002; 277: 39944–39952.
- 421 36. Hoe H-S, Tran TS, Matsuoka Y, Howell BW, Rebeck GW. DAB1 and Reelin Effects on
422 Amyloid Precursor Protein and ApoE Receptor 2 Trafficking and Processing *. *J Biol*
423 *Chem* 2006; 281: 35176–35185.

- 424 37. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al.
425 Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in
426 Late Onset Families. *Science* (80-) 1993; 261: 921–923.
- 427 38. Freudenberg-Hua Y, Li W, Davies P. Effects of Age, Sex, and Ethnicity on the
428 Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-
429 analysis. *Front Med* 2018; 0: 108.
- 430 39. Andrews SJ, Fulton-Howard B, Goate A. Interpretation of risk loci from genome-wide
431 association studies of Alzheimer's disease. *Lancet Neurol* 2020; 19: 326–335.
- 432 40. Bellenguez C, Küçükali F, Jansen IE, Klei L, Moreno-Grau S, Amin N, et al. New
433 insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat*
434 *Genet* 2022 544 2022; 54: 412–436.
- 435 41. Jun G, Vardarajan BN, Buross J, Yu C-E, Hawk M V., Dombroski BA, et al.
436 Comprehensive Search for Alzheimer Disease Susceptibility Loci in the APOE Region.
437 *Arch Neurol* 2012; 69: 1270–1279.
- 438 42. Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buross J, et al. Common
439 variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset
440 Alzheimer's disease. *Nat Genet* 2011 435 2011; 43: 436–441.
- 441 43. Zhou X, Chen Y, Mok KY, Kwok TCY, Mok VCT, Guo Q, et al. Non-coding variability at
442 the APOE locus contributes to the Alzheimer's risk. *Nat Commun* 2019 101 2019; 10:
443 1–16.
- 444 44. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, et
445 al. A TOMM40 variable-length polymorphism predicts the age of late-onset
446 Alzheimer's disease. *Pharmacogenomics J* 2010 105 2009; 10: 375–384.
- 447 45. Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, et al.

- 448 Reduced Reelin Expression Accelerates Amyloid- β Plaque Formation and Tau
449 Pathology in Transgenic Alzheimer's Disease Mice. *J Neurosci* 2010; 30: 9228–9240.
- 450 46. Pujadas L, Rossi D, Andrés R, Teixeira CM, Serra-Vidal B, Parcerisas A, et al. Reelin
451 delays amyloid-beta fibril formation and rescues cognitive deficits in a model of
452 Alzheimer's disease. *Nat Commun* 2014 51 2014; 5: 1–11.
- 453 47. Rice HC, Young-Pearse TL, Selkoe DJ. Systematic evaluation of candidate ligands
454 regulating ectodomain shedding of Amyloid precursor protein. *Biochemistry* 2013;
455 52: 3264–3277.
- 456 48. Rossi D, Gruart A, Contreras-Murillo G, Muhaisen A, Ávila J, Delgado-García JM, et al.
457 Reelin reverts biochemical, physiological and cognitive alterations in mouse models
458 of Tauopathy. *Prog Neurobiol* 2020; 186: 101743.
- 459 49. Gao H, Tao Y, He Q, Song F, Saffen D. Functional enrichment analysis of three
460 Alzheimer's disease genome-wide association studies identifies DAB1 as a novel
461 candidate liability/protective gene. *Biochem Biophys Res Commun* 2015; 463: 490–
462 495.
- 463 50. Botella-López A, Burgaya F, Gavín R, García-Ayllón MS, Gómez-Tortosa E, Peña-
464 Casanova J, et al. Reelin expression and glycosylation patterns are altered in
465 Alzheimer's disease. *Proc Natl Acad Sci U S A* 2006; 103: 5573–5578.
- 466 51. Muller T, Loosse C, Schrotter A, Schnabel A, Helling S, Egensperger R, et al. The AICD
467 Interacting Protein DAB1 is Up-Regulated in Alzheimer Frontal Cortex Brain Samples
468 and Causes Dereglulation of Proteins Involved in Gene Expression Changes. *Curr*
469 *Alzheimer Res* 2011; 8: 573–582.
- 470 52. Chin J, Massaro CM, Palop JJ, Thwin MT, Yu GQ, Bien-Ly N, et al. Reelin Depletion in
471 the Entorhinal Cortex of Human Amyloid Precursor Protein Transgenic Mice and

- 472 Humans with Alzheimer's Disease. *J Neurosci* 2007; 27: 2727–2733.
- 473 53. Howell BW, Lanier LM, Frank R, Gertler FB, Cooper JA. The Disabled 1
474 Phosphotyrosine-Binding Domain Binds to the Internalization Signals of
475 Transmembrane Glycoproteins and to Phospholipids. *Mol Cell Biol* 1999; 19: 5179–
476 5188.
- 477 54. Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of Cytosolic Adaptor Proteins
478 with Neuronal Apolipoprotein E Receptors and the Amyloid Precursor Protein *. *J Biol*
479 *Chem* 1998; 273: 33556–33560.
- 480 55. Perez RG, Soriano S, Hayes JD, Ostaszewski B, Xia W, Selkoe DJ, et al. Mutagenesis
481 Identifies New Signals for β -Amyloid Precursor Protein Endocytosis, Turnover, and the
482 Generation of Secreted Fragments, Including A β 42 *. *J Biol Chem* 1999; 274: 18851–
483 18856.
- 484 56. Howell BW, Herz J. The LDL receptor gene family: signaling functions during
485 development. *Curr Opin Neurobiol* 2001; 11: 74–81.
- 486 57. Shinohara M, Tachibana M, Kanekiyo T, Bu G. Role of LRP1 in the pathogenesis of
487 Alzheimer's disease: evidence from clinical and preclinical studies: Thematic Review
488 Series: ApoE and Lipid Homeostasis in Alzheimer's Disease. *J Lipid Res* 2017; 58:
489 1267–1281.
- 490 58. Chen Y, Durakoglugil MS, Xian X, Herz J. ApoE4 reduces glutamate receptor function
491 and synaptic plasticity by selectively impairing ApoE receptor recycling. *Proc Natl*
492 *Acad Sci U S A* 2010; 107: 12011–12016.
- 493 59. Lane-Donovan C, Philips GT, Wasser CR, Durakoglugil MS, Masiulis I, Upadhaya A, et
494 al. Reelin protects against amyloid β toxicity in vivo. *Sci Signal* 2015; 8.
- 495 60. Bar I, Tissir F, Lambert de Rouvroit C, De Backer O, Goffinet AM. The Gene Encoding


- 496 Disabled-1 (DAB1), the Intracellular Adaptor of the Reelin Pathway, Reveals Unusual
497 Complexity in Human and Mouse *. J Biol Chem 2003; 278: 5802–5812.
- 498 61. D D, Hung K-Y, Tarn W-Y. RBM4 Modulates Radial Migration via Alternative Splicing of
499 Dab1 during Cortex Development. Mol Cell Biol 2018; 38.
- 500 62. Gao Z, Godbout R. Reelin-Disabled-1 signaling in neuronal migration: splicing takes
501 the stage. Cell Mol Life Sci 2012 7013 2012; 70: 2319–2329.
- 502 63. Yano M, Hayakawa-Yano Y, Mele A, Darnell RB. Nova2 Regulates Neuronal Migration
503 through an RNA Switch in Disabled-1 Signaling. Neuron 2010; 66: 848–858.
- 504 64. Howell BW, Gertler FB, Cooper JA. Mouse disabled (mDab1): a Src binding protein
505 implicated in neuronal development. EMBO J 1997; 16: 121–132.
- 506 65. Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, et al. GWAS on
507 family history of Alzheimer’s disease. Transl Psychiatry 2018 81 2018; 8: 1–7.
- 508
- 509

510 **Figure legends**

511

512 **Figure 1:** Manhattan plot for the genome-wide association study in *APOE-ε4* homozygotes

513 with SNP MAF > 5%.




514

515

516


517 **Figure 2:** The cumulative risk of AD among *APOE*- ϵ 4 homozygous of the UK Biobank
518 participants, who carry 0, 1 or 2 risk alleles T the lead SNP (rs112437613) in *DAB1*.



519

520

521 **Figure 3.** Epistatic effect between *APOE-ε4* and rs112437613 (*DAB1*) in the whole sample of
522 the UK Biobank aged 65+ (N=229,748). All log(odds ratio) values are with respect to the
523 baseline homozygote with no counted alleles at both loc. Orange/red bars have negative
524 values. All odds ratios are adjusted for age, sex and principal components.




525

526

527

528 **Figure 4.** REELIN-DAB1 signalling pathway based on studies in mouse neurons and brain
529 (human protein names are shown, created with BioRender.com, see BioRender's Academic
530 License publication licence in the Supplemental material). The pathway branches
531 downstream of the signalling complex. Branch 1 regulates the cell surface expression of
532 CDH2 (N-cadherin) and branch 2 regulates MAPT phosphorylation.



533 **Table 1:** Novel genome-wide significant SNPs in *DAB1*.

CHR	BP	SNP	Closest gene	Current Analysis					Previous LOAD GWAS [65]		
				Effect/Alt	Freq	OR	SE	p-value	Effect/Alt	OR	p-value
1	57625932	rs17541203	<i>DAB1</i>	C/T	0.07	2.19	0.14	2.4x10 ⁻⁸	C/T	0.98	4.8x10 ⁻¹
1	57643271	rs197111	<i>DAB1</i>	T/C	0.07	2.16	0.14	3.1x10 ⁻⁸	T/C	0.98	4.1x10 ⁻¹
1	57646630	rs78921149	<i>DAB1</i>	T/C	0.07	2.22	0.14	1.4x10 ⁻⁸	T/C	0.98	4.2x10 ⁻¹
1	57647715	rs112437613	<i>DAB1</i>	T/C	0.07	2.28	0.14	5.4x10 ⁻⁹	T/C	0.99	5.0x10 ⁻¹
1	57648856	rs17115257	<i>DAB1</i>	G/T	0.08	2.12	0.13	1.0x10 ⁻⁸	G/T	0.99	6.5x10 ⁻¹
1	57650410	rs58359668	<i>DAB1</i>	T/C	0.08	2.12	0.13	1.1x10 ⁻⁸	T/C	0.99	6.5x10 ⁻¹

534

535 CHR –chromosome; BP –base-pair position in build37; SNP –single nucleotide polymorphism, closest gene –genes were annotated with

536 assembly hg19; effect/non-effect –effect and non-effect alleles; freq- frequency of reference allele in the UK Biobank *APOE-ε4* homozygotes

537 individuals; OR, SE, p-value –odds ratio, standard error and p-value of the current and previous reported AD GWAS association studies; GWAS

538 –reference of the corresponding GWAS study

Table 2. Results of the gene-based analyses for the genes in the *DAB1-RELN* pathway accounting for the number of SNPs and the LD structure for each gene using MAGMA software.

GENE	CHR	START	STOP	N SNPs	p-value
AKT1	14	105235686	105262080	76	0.0044
CDH2	18	25530930	25757445	471	0.164
CRK	17	1324647	1359561	90	0.660
CRKL	22	21271714	21308037	86	0.847
CTNND1	11	57520756	57586652	86	0.157
DAB1	1	57460453	58716211	3496	0.004
FYN	6	111981535	112194655	538	0.456
RAPGEF1	9	134452157	134615364	393	0.404
GSK3B	3	119540800	119813264	407	0.840
PDK1	2	173420101	173490351	200	0.546
PDK2	17	48172101	48188733	53	0.143
PIK3CA	3	178866311	178952500	203	0.033
RELN	7	103112231	103629963	1987	0.0069
RAP1A	1	112162405	112256807	307	0.00025
SRC	20	35973088	36033835	133	0.546
VLDLR	9	2621679	2654485	103	0.158
YES1	18	721592	812327	232	0.809
LRP8	1	53708036	53793821	194	0.842
STK25	2	242434122	242449145	45	0.161

GENE –gene annotation with assembly hg19; CHR- chromosome; START, STOP – start and stop base-pair positions for genes; N SNPs- the number of SNPs in the analysis, p-value for the gene-based association test.